ASML's Shareholder Payouts Clash with Cash Burn and Political Headwinds

ASML posts strong Q1 2026 results and raises outlook on AI demand, but negative cash flow and looming US legislation on China sales create investor uncertainty.

ASML Holding NV is rewarding its shareholders handsomely amid record demand for its chipmaking machines, but a stark negative cash flow and looming US legislation present a complex picture for the Dutch tech giant. The company recently posted first-quarter results for 2026 that smashed expectations, yet its stock reaction was muted as investors weighed immediate financial pressures against long-term geopolitical risks.

For the period, ASML reported net sales of 8.8 billion euros and a net profit of 2.8 billion euros, comfortably exceeding consensus estimates. Its gross margin reached 53.0%, hitting the upper end of its guidance. Despite this operational strength, the share price fell approximately five percent on the report’s release. The decline was attributed to a second-quarter revenue forecast that disappointed the market. Management expects Q2 sales between 8.4 and 9.0 billion euros, below the analyst consensus of 9.07 billion euros.

Nevertheless, the company raised its full-year 2026 outlook, now projecting sales between 36 and 40 billion euros, up from a prior range of 34 to 39 billion euros. CEO Christophe Fouquet pointed to unrelenting investment in AI infrastructure as the core driver. "Demand for chips exceeds supply," he stated. "Our customers are accelerating their capacity expansions for 2026 and beyond."

Shareholders are set to benefit directly from this robust performance. The total dividend for 2025 is being increased by 17 percent to 7.50 euros per share. Following three interim dividends of 1.60 euros each, the board will propose a final dividend of 2.70 euros at the upcoming Annual General Meeting. Concurrently, a share buyback program running through the end of 2028, with a total envelope of up to 12 billion euros, is underway. In Q1 alone, ASML repurchased around 0.9 million of its own shares for approximately 1.1 billion euros.

This generous capital return stands in sharp contrast to the company's cash generation last quarter. Free cash flow turned deeply negative, coming in at minus 2.6 billion euros. Consequently, liquid reserves dropped from 13.3 billion euros at the end of 2025 to 8.4 billion euros.

Geopolitical factors are adding another layer of uncertainty. A bipartisan group of US lawmakers has introduced a bill, known as the MATCH Act, which would prohibit ASML from selling its deep ultraviolet (DUV) lithography systems to Chinese chipmakers. While the sale of its most advanced extreme ultraviolet (EUV) machines to China is already banned, DUV systems have remained a key product line in that market. The impact of existing restrictions is already visible in the geographic sales mix. Revenue from China plummeted to 19% of total sales in Q1 2026, down from 36% in the prior quarter. Meanwhile, South Korea and Taiwan dominated, accounting for a combined share of nearly 70%.

Analysts are assessing the potential damage. Michael Roeg of Degroof Petercam estimates any new rules could lead to a single-digit percentage decline in revenue. JPMorgan's Sandeep Deshpande warns that earnings per share could be at risk by up to ten percent.

These risks may be contributing to a significant shift in ASML's market valuation. The stock currently trades at a premium of only about 17% over US competitor Applied Materials, its smallest since 2014. Compared to Lam Research, ASML now trades at a discount of five percent. The shares recently closed at 1,228.40 euros, roughly five percent below their 52-week high, though they maintain a 24% gain year-to-date and a staggering 113% advance over the past twelve months.

Two imminent events will shape the near-term narrative. The company's AGM on April 22 will see votes on the dividend, the appointment of new CTO Marco Pieters, and board expansions. A day later, a US committee is scheduled to decide on the MATCH Act. The future scale of ASML's business in China hinges on that political verdict.